
What Does It Take to Build a Business Around a Single Patient?
Emerging “N-of-1” Models and the Regulatory Road Ahead
Advances in genetic testing and personalized medicine are creating new opportunities for individualized, or “N-of-1,” therapies. As emerging companies explore scalable business models for these treatments, they face evolving regulatory, legal, and ethical considerations that will shape their development and commercialization.
Emerging “N-of-1” Models and the Regulatory Road Ahead
Treasury Proposes to Prohibit U.S. Investment in Chinese Biotech: What It Means for China Licensing Deals
On October 26, 2026, the U.S. Treasury Department published proposed regulations (new 31 C.F.R. Part 851) in the Federal Register implementing the Comprehensive Outbound Investment National Security Act (COINS Act). The proposed regulations would prohibit investments by U.S. persons in Chinese biotechnology companies involved in the development or production of small molecules, biologics, vaccines, cell and gene therapies, and their delivery mechanisms where a biological system is used to modify, enhance, produce, or control them. The regulations also prohibit U.S. persons from establishing joint ventures with Chinese partners to conduct such activities. For companies that in-license drug candidates from Chinese biotechs, the license itself remains permitted, but several deal features that are now market practice (licensor equity, NewCos, profit-share collaborations, and certain governance terms) would carry real risk. Comments are due December 7, 2026. The rule is not yet effective. The “effective date” referenced below is the date of the entry into force of the new regulations, which is likely to be close to the end of the first quarter of 2027.

2025 to First-Half 2026 Marks a Breakout Time for CVRs
Sally Wagner Partin and Sharon Flanagan look at the results of Sidley’s latest survey of contingent value rights (“CVRs”), analyzing recent trends in life sciences public M&A and finding a record share of deals using a CVR, particularly in biopharma and also increasingly in medical devices.
EU Biotech Act I: Parliament and Council back Europe’s biotech competitiveness agenda – SPC incentive now the key battleground
Momentum is building behind the European Biotech Act I. The European Parliament and the Council of the EU broadly back the competitiveness agenda, with strong cross-party support for faster clinical trials, strategic-project funding, and regulatory simplification, and Member States showing less resistance than expected. The supplementary protection certificate (SPC) extension is the main open point – and the clearest test of how far Europe will go to attract biotechnology research, development, manufacturing, and investment.
The Commission presented its proposal in December 2025 (see our initial Sidley blog post here). This update focuses on how the package has evolved since then and what the latest developments in Parliament and the Council mean for biopharmaceutical developers and investors.

Navigating an Uncertain Market Amidst Cautious Optimism: Steps Biotech Companies Can Take to Hedge Against Financial Fluctuations
As global markets continue to contend with a complex mix of macroeconomic pressures, development-stage biotech companies are being urged to proactively strengthen their financial resilience. The ability to anticipate and respond to liquidity challenges has become a defining factor in determining which companies emerge from this period of volatility with momentum and stability.
Now Is The Right Time For A Hong Kong Biotech Listing
Hong Kong has recently emerged as the number one IPO venue globally, and one of the sectors driving this is biotech. For China-based biotechs looking to float, Hong Kong is a natural destination. But biotechs based anywhere in the world may wish to ride the current wave, as Meng Ding explains.

Will the EU Become the Most Attractive Place for Life Sciences? How the EU Woos Biotech
The European Commission made a lofty commitment in its recently published Life Sciences Strategy to position the EU as the world’s most attractive place for life sciences by 2030. To succeed with this vision, EU lawmakers must ensure that these efforts will truly cut red tape and accelerate innovation rather than simply adding new layers of regulation. They must also ensure that these efforts are not undermined by other legislative changes affecting the EU’s biotech industry.

Hong Kong’s Biotech Listings Emerge From Two-Year Downturn With 18As Booming
Biotech and medtech startups based in the People’s Republic of China (P.R.C.) are flocking to Hong Kong to float. Meng Ding explains how a combination of listing reforms and an explosion of innovation in the Greater Bay Area have led to Hong Kong’s 18A process being popular for life sciences.

